Table 3.

Logistic regression models assessing the associations of TG and lipid ratios with increased UACR

	Unadjusted		Model 1		Model 2		Model 3	Model 4
	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	P value
Female
TG
Q1	1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)
Q2	1.29(1.16–1.44)	< 0.001	1.11(0.99–1.24)	0.083	1.06(0.94–1.19)	0.339	0.99(0.88–1.11)	0.862	0.99(0.88–1.11)	0.819
Q3	1.65(1.48–1.83)	< 0.001	1.26(1.13–1.41)	< 0.001	1.14(1.02–1.28)	0.022	1.03(0.92–1.16)	0.619	1.02(0.91–1.15)	0.688
Q4	2.19(1.98–2.43)	< 0.001	1.64(1.47–1.83)	< 0.001	1.41(1.26–1.57)	< 0.001	1.16(1.03–1.30)	0.013	1.15(1.02–1.29)	0.021
TG/HDL-C
Q1	1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)
Q2	1.59(1.42–1.78)	< 0.001	1.33(1.18–1.49)	< 0.001	1.27(1.13–1.43)	< 0.001	1.20(1.07–1.36)	0.002	1.20(1.07–1.35)	0.003
Q3	1.87(1.67–2.08)	< 0.001	1.40(1.24–1.57)	< 0.001	1.27(1.13–1.43)	< 0.001	1.13(1.00–1.27)	0.044	1.13(1.00–1.27)	0.051
Q4	2.55(2.29–2.83)	< 0.001	1.81(1.62–2.03)	< 0.001	1.58(1.41–1.78)	< 0.001	1.29(1.15–1.46)	< 0.001	1.28(1.13–1.44)	< 0.001
Non-HDL-C/HDL-C
Q1	1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)
Q2	1.09(0.99–1.21)	0.088	1.08(0.97–1.20)	0.165	1.03(0.92–1.14)	0.644	0.98(0.88–1.10)	0.755	0.98(0.88–1.10)	0.735
Q3	1.17(1.06–1.30)	0.002	1.17(1.06–1.31)	0.003	1.08(0.97–1.21)	0.147	0.98(0.88–1.09)	0.704	0.97(0.87–1.09)	0.642
Q4	1.42(1.28–1.56)	< 0.001	1.51(1.36–1.68)	< 0.001	1.34(1.20–1.49)	< 0.001	1.14(1.02–1.27)	0.024	1.13(1.01–1.26)	0.034
Male
TG
Q1	1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)
Q2	1.07(0.90–1.28)	0.454	1.01(0.85–1.21)	0.898	0.90(0.75–1.08)	0.267	0.85(0.70–1.03)	0.093	0.85(0.70–1.03)	0.092
Q3	1.38(1.17–1.64)	< 0.001	1.32(1.11–1.57)	0.001	1.06(0.89–1.27)	0.520	0.97(0.81–1.17)	0.742	0.97(0.80–1.16)	0.704
Q4	1.60(1.36–1.89)	< 0.001	1.66(1.40–1.97)	< 0.001	1.19(0.99–1.43)	0.058	1.06(0.87–1.28)	0.578	1.05(0.87–1.26)	0.643
TG/HDL-C
Q1	1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)
Q2	1.20(1.00–1.44)	0.046	1.17(0.97–1.40)	0.100	1.04(0.86–1.25)	0.702	0.98(0.81–1.19)	0.858	0.98(0.81–1.19)	0.831
Q3	1.47(1.23–1.74)	< 0.001	1.40(1.17–1.67)	< 0.001	1.14(0.94–1.37)	0.176	1.05(0.87–1.27)	0.626	1.04(0.86–1.26)	0.671
Q4	1.86(1.58–2.20)	< 0.001	1.90(1.60–2.27)	< 0.001	1.41(1.17–1.70)	< 0.001	1.25(1.03–1.51)	0.024	1.24(1.02–1.50)	0.032
Non-HDL-C/HDL-C
Q1	1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)		1.00(reference)
Q2	1.05(0.89–1.25)	0.546	1.08(0.91–1.29)	0.358	0.97(0.81–1.15)	0.704	0.94(0.79–1.13)	0.528	0.94(0.79–1.13)	0.506
Q3	1.05(0.89–1.24)	0.591	1.12(0.95–1.33)	0.184	0.95(0.79–1.13)	0.552	0.87(0.73–1.05)	0.144	0.87(0.72–1.04)	0.131
Q4	1.29(1.10–1.52)	0.002	1.57(1.32–1.85)	< 0.001	1.21(1.01–1.45)	0.036	1.11(0.92–1.33)	0.287	1.10(0.91–1.32)	0.329

Model 1: adjusted for center, age.

Model 2: additionally adjusted for ALT, γ-GGT, BMI, smoking, drinking, cardiovascular disease, eGFR.

Model 3: additionally adjusted for HbA1c, SBP, DBP, pulse and use of anti-diabetic medication.

Model 4: additionally adjusted for HOMA-IR.

Abbreviations: UACR urinary albumin-creatinine ratio; OR odds ratio; CI confidence interval; TG triglyceride; HDL-C high-density lipoprotein cholesterol; non-HDL-C non-high-density lipoprotein cholesterol; eGFR estimated glomerular filtration rate; ALT alanine transaminase; γ-GGT γ-glutamyl transpeptidase; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; HbA1c hemoglobin A1c; HOMA-IR homeostasis model assessment of insulin resistance